Mutant peptides and methods of treating subjects using the same
The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating autoimmune disease using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
1. A composition comprising a pre-implantation factor (PIF) analog, wherein the PIF analog comprises an amino acid sequence, wherein:
(a) the amino acid sequence is at least 93% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; or
(b) the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, or a pharmaceutically acceptable salt thereof, and
wherein the composition is free of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 11.
2. The composition of claim 1 , wherein the PIF analog comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising:
i) a therapeutically effective amount of the composition of claim 1 ; and
ii) a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein the PIF analog comprises the amino acid sequence that is at least 93% identical to the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.
5. The pharmaceutical composition of claim 3 , wherein the therapeutically effective amount is from about 1 milligram to about 4 grams.
6. The pharmaceutical composition of claim 3 , wherein the therapeutically effective amount is about 70 milligrams.
7. A method of treating autoimmune disease in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising:
i) a therapeutically effective amount of at least one PIF analog, wherein the PIF analog comprises an amino acid sequence, wherein:
(a) the amino acid sequence is at least 93% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; or
(b) the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6,
or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier;
wherein the pharmaceutical composition is free of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 11,
and wherein the autoimmune disease is graft-versus-host disease, type 1 diabetes, or multiple sclerosis.
8. The method of claim 7 , wherein the pharmaceutically acceptable carrier is sterile and pyrogen-free water or sterile and pyrogen-free Lactated ringer's solution.
9. The method of claim 7 , wherein the therapeutically effective amount is from about 0.1 mg/kg to about 1.0 mg/kg.
10. The method of claim 7 , wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5.0 mg/kg.
11. The method of claim 7 , wherein the PIF analog is at least one of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.
12. The method of claim 7 , wherein the step of administering to the subject the pharmaceutical composition comprises administering a therapeutically effective amount of the PIF analog or pharmaceutically acceptable salt thereof from about 0.001 mg/kg to about 200 mg/kg.
13. The method of claim 7 , wherein the step of administering to the subject the pharmaceutical composition comprises administering a therapeutically effective amount of the PIF analog or pharmaceutically acceptable salt thereof from about 0.5 mg/kg to about 5 mg/kg.
14. The method of claim 7 , wherein the autoimmune disease is multiple sclerosis.
15. The method of claim 7 , wherein the autoimmune disease is type 1 diabetes.
16. The method of claim 7 , wherein the autoimmune disease is graft-versus-host disease.
17. A method of treating diabetes in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising:
i) a therapeutically effective amount of at least one PIF analog, wherein the PIF analog comprises an amino acid sequence, wherein:
(a) the amino acid sequence is at least 93% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; or
(b) the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6,
or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier;
and wherein the pharmaceutical composition is free of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 11.
18. The method of claim 17 , wherein the pharmaceutically acceptable carrier is sterile and pyrogen-free water or sterile and pyrogen-free Lactated ringer's solution.
19. The method of claim 17 , wherein the therapeutically effective amount is from about 0.1 mg/kg to about 1.0 mg/kg.
20. The method of claim 17 , wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5.0 mg/kg.
21. The method of claim 17 , wherein the PIF analog is at least one of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.
22. The method of claim 17 , wherein the pharmaceutical composition is administered intravenously, intramuscularly, topically, intradermally, transmucosally, subcutaneously, sublingually, transdermally, orally, buccally, intraocularly, intravaginally, intrarectally, intraductally, intrathecally, subdurally, extradurally, intraventricularly, intraarticularly, intraperitoneally; into the pleural cavity; by inhalation; by depot injections; or by implants.
23. A method of binding an insulin degrading enzyme (IDE) in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising:
i) a therapeutically effective amount of at least one pre-implantation factor (PIF) analog, wherein the PIF analog comprises an amino acid sequence, wherein:
(a) the amino acid sequence is at least 93% identical to the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; or
(b) the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6,
or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier;
wherein the pharmaceutical composition is free of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 11.
24. The method of claim 23 , wherein the PIF analog is at least one of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a pharmaceutically acceptable salt thereof.